Sophie Wilkinson

Fei Yu Guan, Ian Keefe, Sophie Wilkinson et al.

Boundary detection of irregular and translucent objects is an important problem with applications in medical imaging, environmental monitoring and manufacturing, where many of these applications are plagued with scarce labeled data and low in situ computational resources. While recent image segmentation studies focus on segmentation mask alignment with ground-truth, the task of boundary detection remains understudied, especially in the low data regime. In this work, we present a lightweight discrete diffusion contour refinement pipeline for robust boundary detection in the low data regime. We use a Convolutional Neural Network(CNN) architecture with self-attention layers as the core of our pipeline, and condition on a segmentation mask, iteratively denoising a sparse contour representation. We introduce multiple novel adaptations for improved low-data efficacy and inference efficiency, including using a simplified diffusion process, a customized model architecture, and minimal post processing to produce a dense, isolated contour given a dataset of size <500 training images. Our method outperforms several SOTA baselines on the medical imaging dataset KVASIR, is competitive on HAM10K and our custom wildfire dataset, Smoke, while improving inference framerate by 3.5X.

James K Ruffle, Samia Mohinta, Guilherme Pombo et al.

The benefits of artificial intelligence (AI) human partnerships-evaluating how AI agents enhance expert human performance-are increasingly studied. Though rarely evaluated in healthcare, an inverse approach is possible: AI benefiting from the support of an expert human agent. Here, we investigate both human-AI clinical partnership paradigms in the magnetic resonance imaging-guided characterisation of patients with brain tumours. We reveal that human-AI partnerships improve accuracy and metacognitive ability not only for radiologists supported by AI, but also for AI agents supported by radiologists. Moreover, the greatest patient benefit was evident with an AI agent supported by a human one. Synergistic improvements in agent accuracy, metacognitive performance, and inter-rater agreement suggest that AI can create more capable, confident, and consistent clinical agents, whether human or model-based. Our work suggests that the maximal value of AI in healthcare could emerge not from replacing human intelligence, but from AI agents that routinely leverage and amplify it.

James K Ruffle, Samia Mohinta, Guilherme Pombo et al.

Brain tumour imaging assessment typically requires both pre- and post-contrast MRI, but gadolinium administration is not always desirable, such as in frequent follow-up, renal impairment, allergy, or paediatric patients. We aimed to develop and validate a deep learning model capable of predicting brain tumour contrast enhancement from non-contrast MRI sequences alone. We assembled 11089 brain MRI studies from 10 international datasets spanning adult and paediatric populations with various neuro-oncological states, including glioma, meningioma, metastases, and post-resection appearances. Deep learning models (nnU-Net, SegResNet, SwinUNETR) were trained to predict and segment enhancing tumour using only non-contrast T1-, T2-, and T2/FLAIR-weighted images. Performance was evaluated on 1109 held-out test patients using patient-level detection metrics and voxel-level segmentation accuracy. Model predictions were compared against 11 expert radiologists who each reviewed 100 randomly selected patients. The best-performing nnU-Net achieved 83% balanced accuracy, 91.5% sensitivity, and 74.4% specificity in detecting enhancing tumour. Enhancement volume predictions strongly correlated with ground truth (R2 0.859). The model outperformed expert radiologists, who achieved 69.8% accuracy, 75.9% sensitivity, and 64.7% specificity. 76.8% of test patients had Dice over 0.3 (acceptable detection), 67.5% had Dice over 0.5 (good detection), and 50.2% had Dice over 0.7 (excellent detection). Deep learning can identify contrast-enhancing brain tumours from non-contrast MRI with clinically relevant performance. These models show promise as screening tools and may reduce gadolinium dependence in neuro-oncology imaging. Future work should evaluate clinical utility alongside radiology experts.